|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:awarded
|
gptkb:2021_Princess_of_Asturias_Award_for_Technical_and_Scientific_Research
|
|
gptkbp:CEO
|
gptkb:Stéphane_Bancel
|
|
gptkbp:collaboratedWith
|
gptkb:U.S._National_Institutes_of_Health
|
|
gptkbp:countryOfOrigin
|
gptkb:United_States
|
|
gptkbp:COVID-19_vaccineBrandName
|
gptkb:Spikevax
|
|
gptkbp:developedBy
|
vaccine
|
|
gptkbp:focusesOn
|
infectious diseases
vaccines
immuno-oncology
rare diseases
mRNA therapeutics
|
|
gptkbp:foundedYear
|
2010
|
|
gptkbp:founder
|
gptkb:Robert_S._Langer
gptkb:Derrick_Rossi
gptkb:Kenneth_R._Chien
gptkb:Noubar_Afeyan
gptkb:Stéphane_Bancel
|
|
gptkbp:fundedBy
|
gptkb:U.S._government
gptkb:Operation_Warp_Speed
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_Massachusetts,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Moderna
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Juan_Andres
gptkb:Melissa_J._Moore
gptkb:Noubar_Afeyan
gptkb:Paul_Burton
gptkb:Stéphane_Bancel
gptkb:Stephen_Hoge
|
|
gptkbp:listedOn
|
gptkb:Forbes_Global_2000
|
|
gptkbp:marketCap
|
varies (over $50 billion in 2021)
|
|
gptkbp:notableProduct
|
gptkb:Spikevax
gptkb:mRNA-1273
|
|
gptkbp:numberOfEmployees
|
~5,000 (2023)
|
|
gptkbp:parentCompany
|
independent
|
|
gptkbp:patent
|
gptkb:mRNA_vaccine_technology
|
|
gptkbp:researchInterest
|
messenger RNA (mRNA)
|
|
gptkbp:stockSymbol
|
gptkb:MRNA
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
https://www.modernatx.com/
|
|
gptkbp:bfsParent
|
gptkb:Robert_Langer
|
|
gptkbp:bfsLayer
|
3
|